Alexander Hardy
Known title: Chief Executive OfficerCIK: 0002001910
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 4,252 | $238K | 3/17/2026 | View on chart |
| BMRN | ▲ Buy | Grant | 62,440 | $0 | 3/16/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 2,941 | $172K | 3/13/2026 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 16,570 | $912K | 12/1/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 375 | $20K | 4/30/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 44,360 | $0 | 3/17/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 2,933 | $204K | 3/14/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 14,295 | $944K | 11/29/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 300 | $17K | 10/31/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 32,780 | $0 | 3/15/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 68,039 | $0 | 12/1/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 47,332 | $0 | 12/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.